Levin Albert M, Okifo Oghenefejiro, Buhl Katherine, Ouchi Takahiro, Parker Bianca, Tan Jessica, Datta Indrani, Dai Xiangguo, Chen Yalei, Palanisamy Nallasivam, Veenstra Jesse, Carskadon Shannon, Li Jia, Ozog David, Keller Christian E, Chitale Dhananjay, Bobbitt Kevin R, Crawford Howard C, Steele Nina, Mi Qing-Sheng, Jones Lamont R
Department of Public Health Science Henry Ford Health Detroit Michigan USA.
Center for Bioinformatics Henry Ford Health Detroit Michigan USA.
Laryngoscope Investig Otolaryngol. 2024 Dec 11;9(6):e70040. doi: 10.1002/lio2.70040. eCollection 2024 Dec.
In this study, we aimed to evaluate mir-31-5p as a prognostic biomarker of keloid disease (KD) recurrence using a retrospective, treatment naïve, surgical cohort of head and neck KD cases from Henry Ford Health.
Using a tissue microarray, mir-31-5p expression was measured with miRNAscope, and mir-31-5p cell positivity was determined with QuPath. Logistic regression was used to test the association between mir-31-5p positive cells and KD recurrence at 1 year. In an independent dataset, associations between mir-31-5p and messenger RNA (mRNA) expression were assessed. Ingenuity Pathway Analysis identified target genes and pathways impacted by mir-31-5p.
Of the 58 KD patients, 42 (72%) received adjuvant triamcinolone injections, and 8 recurred (14%). mir-31-5p was expressed in 48 (83%) specimens. Increasing mir-31-5p expression was associated with decreased risk of recurrence ( = .031), with an odds ratio of 0.86 (95% CI 0.75-0.98) for each 20% increase in mir-31-5p cellular positivity. This effect persisted with triamcinolone treatment (odds ratio 0.82; 95% CI 0.71-0.95; = .015). mir-31-5p correlated with gene expression enriched in KD pathways, including mRNA splicing and autophagy.
Taken together, our data supports the association between mir-31-5p expression and KD recurrence. Its potential as a prognostic biomarker should be further investigated.
Level 2.
在本研究中，我们旨在使用来自亨利福特健康中心的一组未经治疗的头颈部瘢痕疙瘩疾病（KD）手术病例的回顾性队列，评估mir-31-5p作为瘢痕疙瘩疾病复发的预后生物标志物。
使用组织微阵列，通过miRNAscope测量mir-31-5p表达，并使用QuPath确定mir-31-5p细胞阳性率。采用逻辑回归检验mir-31-5p阳性细胞与1年时KD复发之间的关联。在一个独立的数据集中，评估mir-31-5p与信使核糖核酸（mRNA）表达之间的关联。 Ingenuity通路分析确定了受mir-31-5p影响的靶基因和通路。
58例KD患者中，42例（72%）接受了曲安奈德辅助注射，8例复发（14%）。48例（83%）标本中表达了mir-31-5p。mir-31-5p表达增加与复发风险降低相关（P = 0.031），mir-31-5p细胞阳性率每增加20%，比值比为0.86（95%可信区间0.75-0.98）。曲安奈德治疗后这种效应持续存在（比值比0.82；95%可信区间0.71-0.95；P = 0.015）。mir-31-5p与KD通路中富集的基因表达相关，包括mRNA剪接和自噬。
综上所述，我们的数据支持mir-31-5p表达与KD复发之间的关联。其作为预后生物标志物的潜力应进一步研究。
2级。
